Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.
UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.
In findings published in Clinical Cancer Research, a research team at Mayo Clinic identified specific proteins—fibronectin and smooth muscle actin—within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
The Center for Drug Evaluation of China’s National Medical Products Administration granted Breakthrough Therapy designation to olverembatinib, combination with low-intensity chemotherapy, for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
FDA granted Orphan Drug designation to rhenium obisbemeda (186Re) for the treatment of leptomeningeal metastases in patients with lung cancer.
Amid the flood zone of today’s Washington, the confirmation hearing for Jayanta (Jay) Bhattacharya’s nomination as director of NIH was remarkably calm.
In a speech before a joint session of Congress, President Trump briefly addressed pediatric cancer, pointing to a 13-year old brain tumor survivor, Devarjaye “DJ” Daniel, who was watching from the gallery, making his dream come true by naming him a Secret Service agent.
Each year, nearly 14 million people in the U.S. contract human papillomavirus, a common, sexually-transmitted virus that can cause several cancers.
As cancer specialists, we have to constantly be on the lookout, alert for trends as they emerge—because they might impact the way we best deliver advice or care, or because trends may inform us about specific influences that drive cancers.
